Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias (HUGTiP-IGTP), 08916 Badalona, Spain.
Departments of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.
Medicina (Kaunas). 2020 Jun 23;56(6):309. doi: 10.3390/medicina56060309.
Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration.
A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans.
The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration.
Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.
一些国家的大麻合法化法规的变化影响了大麻使用的多样化。目前可获得的大麻形式越来越多,无论是娱乐还是治疗用途,这些大麻形式都越来越受欢迎。从治疗的角度来看,含有 Δ-9-四氢大麻酚(THC)和大麻二酚(CBD)的口服大麻是一种很有前途的给药途径,但关于其在人体中的药代动力学(PK)效应的信息仍然很少。本系统评价的目的是提供关于口服大麻和 THC 的 PK 数据的综合概述。
使用 PubMed 数据库对已发表的文献进行了搜索,以收集描述人类口服 THC 的 PK 数据的可用文章。
文献搜索产生了 363 个结果,其中 26 个符合我们的纳入标准。已经研究了口服 THC 的 PK 数据,使用的制剂包括胶囊(包括油含量)、片剂、烘焙食品(布朗尼和饼干)以及油和茶(煎剂)。胶囊和片剂主要对应于制药形式,是最常研究的口服制剂。总体而言,结果反映了口服制剂中 THC 吸收的高度可变性,与其他给药途径相比,峰值血浆浓度延迟。
口服 THC 的 PK 特征具有高度可变性,不同制剂之间存在差异,烘焙食品和油类制剂的可变性似乎更高。总体而言,该领域的可用信息有限。因此,需要进一步研究以揭示口服 THC 给药的不可预测性,从而提高药用口服制剂的有效性和安全性。